Recommended Readings: James P. Allison, Ph.D., Friday May 12th, 2017

Friday Lectures

Friday, May 2, 2017  3:45 p.m.

Caspary Auditorium

James P. Allison, Ph.D.

Professor and Vivian L. Smith Distinguished Chair of Immunology,

Executive Director of the Immunotherapy Platform

The University of Texas MD Anderson Cancer Center

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for a Cure

Recommended Readings:

http://thetartan.org/2017/5/1/scitech/immunotherapy

Hazarika M; Chuk MK; Theoret MR; et al. (2017). U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.CLINICAL CANCER RESEARCH. doi: 10.1158/1078-0432

Medina, Patrick J.; Adams, Val R. (2016). PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. PHARMACOTHERAPY. 36(3): 317-334

Sharma, Padmanee; Allison, James P. (2015). Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. CELL. 161(2): 205-214

Robert, Caroline; Schachter, Jacob; Long, Georgina V.; et al. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. NEW ENGLAND JOURNAL OF MEDICINE    372(26): 2521-2532

Sharma, Padmanee; Allison, James P. (2015). The future of immune checkpoint therapy. SCIENCE. 348(6230): 56-61

Gubin, Matthew M.; Zhang, Xiuli; Schuster, Heiko; et al. (2014). Checkpoint blockage cancer immunotherapy targets tumour-specific mutant antigens. NATURE. 515(7528): 577-+

Lipson, Evan J.; Drake, Charles G. (2011). Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. CLINICAL CANCER RESEARCH. 17(22): 6958-6962

 

Recommended Readings: Michel C. Nussenzweig, M.D., Ph.D.

Friday Lecture Series

Ph.D. Recruitment Lecture

The HIV Vaccine Problem

Michel C. Nussenzweig, M.D., Ph.D., Sherman Fairchild Professor,

senior physician, The Rockefeller University;

investigator, Howard Hughes Medical Institute

 March 8, 2012

3:45 p.m.-5:00 p.m. (Refreshments, 3:15 p.m., Abby Lounge)

Caspary Auditorium

 

Recommended Readings

Mouquet, H., Warncke, M., Scheid, J. F., Seaman, M. S., & Nussenzweig, M. C. (2012). Enhanced HIV-1 neutralization by antibody heteroligation. Proceedings of the National Academy of Sciences of the United States of America, 109(3), 875-880

Nchinda, G., Kuroiwa, J., Oks, M., Trumpfheller, C., Chae, G. P., Huang, Y., . . . Steinman, R. M. (2008). The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. Journal of Clinical Investigation, 118(4), 1427-1436

Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., . . . Nussenzweig, M. C. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 333(6049), 1633-1637

Trumpfheller, C., Finke, J. S., López, C. B., Moran, T. M., Moltedo, B., Soares, H., . . . Steinman, R. M. (2006). Intensified and protective CD4 + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. Journal of Experimental Medicine, 203(3), 607-617

Zhou, T., Georgiev, I., Wu, X., Yang, Z. -., Dai, K., Finzi, A., . . . Kwong, P. D. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 329(5993), 811-817

Recommended Readings: Bruce Walker, M.D.

Friday Lecture Series

Immune Control and Immune Failure in HIV Infection

Bruce Walker, M.D., Principal Investigator,

Ragon Institute of MGH, MIT and Harvard

April 13, 2012

3:45 p.m.-5:00 p.m. (Refreshments, 3:15 p.m., Abby Lounge)

Caspary Auditorium

 

Recommended Readings:

Huang, J., P. S. Burke, T. D. H. Cung, F. Pereyra, I. Toth, B. D. Walker, L. Borges, M. Lichterfeld, and X. G. Yu. 2010. “Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers.” Journal of Virology 84 (18): 9463-9471

Kawashima, Y., K. Pfafferott, J. Frater, P. Matthews, R. Payne, M. Addo, H. Gatanaga, et al. 2009. “Adaptation of HIV-1 to Human Leukocyte Antigen Class I.” Nature 458 (7238): 641-645

Mahalanabis, M., P. Jayaraman, T. Miura, F. Pereyra, E. M. Chester, B. Richardson, B. Walker, and N. L. Haigwood. 2009. “Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers.” Journal of Virology 83 (2): 662-672

Matthews, P. C., A. Prendergast, A. Leslie, H. Crawford, R. Payne, C. Rousseau, M. Rolland, et al. 2008. “Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point.” Journal of Virology 82 (17): 8548-8559

Pereyra, F., S. Palmer, T. Miura, B. L. Block, A. Wiegand, A. C. Rothchild, B. Baker, et al. 2009. “Persistent Low-Level Viremia in HIV-1 Elite Controllers and Relationship to Immunologic Parameters.” Journal of Infectious Diseases 200 (6): 984-990

Virgin, H. W. and B. D. Walker. 2010. “Immunology and the Elusive AIDS Vaccine.” Nature 464 (7286): 224-231